Skip to content

Company
Pipeline
For Investors
Contact

Company
Pipeline
For Investors
Contact

Press Releases

Choose Year
Search Press Releases

Found 270 Results

January 13, 2015

Relmada Therapeutics Reaches Midway Point in Dose Escalation for Phase One Study of Novel NMDA Receptor Antagonist d-Methadone

January 7, 2015

Relmada Therapeutics to Present at OneMedForum in San Francisco

January 6, 2015

Relmada Therapeutics to Provide Corporate Update at 2015 Biotech Showcase™ in San Francisco

December 22, 2014

Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone

December 18, 2014

Relmada Therapeutics Announces Results of Annual Shareholders Meeting

December 10, 2014

Relmada Therapeutics Appoints Christine Silverstein as Director of Investor Relations

December 3, 2014

Relmada Therapeutics Nominated for Buzz of BIO Contest at the 2015 BIO CEO & Investor Conference

December 2, 2014

Relmada Therapeutics Receives Health Canada Clearance to Commence First Clinical Study of d-Methadone

November 24, 2014

Relmada Therapeutics To Present At LD MICRO Conference

November 4, 2014

Relmada Therapeutics Appoints Michael Becker As Senior Vice President Of Finance And Corporate Development

«...22 23 24 252627

IR Contact

Brian Ritchie
LifeSci Advisors, LLC

+1 (212) 915-2578
britchie@lifesciadvisors.com

Email Alerts Sign-Up

Email

I accept the Privacy Policy^*

Unsubscribe

Loading...

Company

Pipeline
Overview
NDV-01
Speranolone

For Investors
Summary
News
Events
SEC Filings
Corporate Governance
Stock Information

Contact

info@relmada.com

+1 (786) 629-1376

©2026 Relmada Therapeutics, Inc.

Privacy Policy
Terms of Use

Scroll to Top